Last updated: February 25, 2026
What is NDC 00555-0971?
NDC 00555-0971 corresponds to Eliquis (apixaban), an oral anticoagulant used primarily for stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and thromboprophylaxis following hip or knee replacement surgery. Eliquis was developed by Bristol-Myers Squibb and Pfizer, approved by the FDA in 2012.
Market Overview
Market Size and Growth
- Global anticoagulants market is valued at approximately USD 8 billion in 2022.
- Expected CAGR from 2022 to 2029 is around 7.3% (Grand View Research, 2022).
- Eliquis represents a leading share, accounting for 32% of the oral anticoagulant segment (IQVIA, 2022).
Market Drivers
- Rising prevalence of atrial fibrillation and VTE conditions.
- Increasing adoption of oral anticoagulants over warfarin due to safer profiles and fewer monitoring requirements.
- Growing geriatric population prone to thromboembolic events.
Competitive Landscape
- Primary competitors: Xarelto (rivaroxaban), Savaysa (edoxaban), Dabigatran.
- Market share distribution (2022): Eliquis 35%, Xarelto 30%, others 35% (IQVIA).[1]
- Patent expiration dates will influence pricing and generic competition.
Patent and Regulatory Status
- Original patent expiry for Eliquis in the U.S.: December 2026.
- Patent protections restrict generic entry until legal challenges or patent expiration.
- No immediate generics anticipated before 2026, maintaining pricing power.
Price Trends and Projections
Current Pricing (U.S.)
- Estimated retail price per 30-day supply: USD 500–USD 600.
- Medicaid average reimbursement: USD 400–USD 500.
- Price variations exist depending on packaging and pharmacy discounts.
Historical Price Trends
| Year |
Average Price per 30-day Supply |
Remarks |
| 2013 |
USD 560 |
Shortly after FDA approval, initial pricing. |
| 2018 |
USD 530 |
Slight decline due to early competition. |
| 2022 |
USD 510 |
Stable with limited generic activity. |
Price Projection (Next 5 Years)
| Year |
Expected Price Range |
Assumptions |
| 2023 |
USD 510 – USD 530 |
Limited competition. |
| 2024 |
USD 500 – USD 530 |
Increased insurance negotiations. |
| 2025 |
USD 490 – USD 520 |
Patent expiration approaches. |
| 2026 |
USD 470 – USD 500 |
Entry of generics pending patent expiry. |
| 2027+ |
USD 250 – USD 350 (post-generic) |
Generic entry reduces price sharply. |
Factors Influencing Future Prices
- Patent litigation outcomes and timing of patent expiration.
- Entry of generic versions and biosimilars.
- Insurance coverage policies and formulary positioning.
- Domestic pricing regulations and healthcare policies.
Implications for Stakeholders
- Pharmaceutical companies: Potential revenue decline post-generic entry; need for lifecycle management strategies.
- Healthcare providers: Cost pressures from high-priced branded drugs may shift with generics.
- Insurers: Increasing pressure to negotiate lower prices; formulary restrictions.
- Investors: Strong market position until patent expiry; valuation risks increase with patent challenges and generic competition.
Key Takeaways
- NDC 00555-0971 (Eliquis) holds a dominant market position with stable prices until patent expiry in late 2026.
- Market growth driven by rising thromboembolic disease prevalence and preference for oral anticoagulants.
- Price projections indicate stability through 2023–2025; substantial declines likely after 2026 due to patent expiration and generic competition.
- Competitive landscape is concentrated; patent strategies, litigation, and innovation will influence long-term market dynamics.
Frequently Asked Questions
Q1: When will generic versions of Eliquis become available in the U.S.?
A1: Likely post-December 2026, assuming patent protections are not extended or litigated successfully.
Q2: How does Eliquis pricing compare with its competitors?
A2: Eliquis's current price per 30-day supply is approximately USD 510–USD 600, similar or slightly higher than Xarelto; prices tend to converge following generic entry.
Q3: What factors could accelerate or delay generic entry?
A3: Patent litigation outcomes, settlement agreements, regulatory delays, and legal challenges influence timing.
Q4: How will insurance coverage influence patient access?
A4: Favorable formulary placement and negotiated discounts can mitigate high out-of-pocket costs, affecting utilization.
Q5: What strategies can Bristol-Myers Squibb and Pfizer employ to sustain revenue?
A5: Lifecycle management with new formulations, expanded indications, or combination therapies may extend market share beyond patent expiration.
References
[1] IQVIA. (2022). Market report on anticoagulants. IQVIA Pharma Data.
